Eric joined Delos Capital as a Senior Advisor in 2020 and served as an Operating Partner before transitioning to a full-time Partner in 2024.
Prior to Delos, Eric held various leadership roles at Moderna Therapeutics, including as founding CSO of Moderna’s New Venture Labs, an industry-leading effort to explore novel applications of mRNA technology across immunology, neurology, tissue repair & regeneration, and cancer. In this role, he conceived of Moderna’s mRNA vaccine platform, which later led to the development of the COVID-19 vaccine. Eric was recognized for this work with the prestigious Warren Alpert Foundation Prize. Additionally, Eric oversaw the invention of Moderna’s personalized cancer vaccine, now in late-stage clinical development with Merck, and the company’s first autoimmune program from inception through IND. Most recently, Eric served as General Manager and Chief Scientific Officer (CSO) at Moderna Genomics.
Eric’s earlier career included roles of increasing responsibility in corporate and business development at venture-backed biotechnology companies, including Seaside Therapeutics, Stromedix, and Domantis.
Eric holds a Ph.D. in Molecular and Medical Parasitology from New York University and an MBA from Boston University. He also earned a B.S. from Emory University and is a proud Rocker with an A.A. from Bard College at Simon’s Rock.